We’ve gone through blood, sweat, and tears to get here. This validates everything we’ve built,' Saldanha said.

AbbVie Inc. (NYSE:ABBV) saw its stock jump 3.4% after announcing a major licensing agreement with IGI Therapeutics, securing ...

IGI Therapeutics SA, a wholly-owned subsidiary of Ichnos Glenmark Innovation (IGI)—an alliance between Glenmark Pharma and Ichnos Sciences Inc.—has signed an exclusive licensing agreement with AbbVie ...

Biopharma company AbbVie will acquire Capstan Therapeutics for up to $2.1 billion in cash, giving it access to promising new ...

What factors contribute to India’s lag in R&D spending? Why is R&D central to boosting MSME performance? Rohinton Sidhwa, Partner, Deloitte India, said that R&D boosts innovation and has a remarkable ...

The last few years have seen a huge increase in currency-related costs and fractured trade relations. Locally sourced R&D can give MSMEs and startups a huge advantage,” he says.

For AI to become an effective team player with humans, it needs to develop what psychologists call theory of mind—in R&D, this would mean an understanding of scientists’ often tacit objectives. Kaski ...

AbbVie is deploying more capital into its pipeline, which features 50 programs in mid- and late-stage development and over 375 clinical trials. See why ABBV stock is a Buy.

A revolution for R&D with the missing link of machine learning — project envisions human-AI expert teams to solve grand challenges Robust, deployable and collaborative machine learning (ML ...

AbbVie is undervalued with strong EPS growth, rising immunology revenue, and a 3.43% yield. Check out ABBV's robust pipeline and long-term value.

ABSTRACT: Evaluating drug safety during pregnancy remains an ongoing clinical and pharmacological challenge due to ethical, practical, and regulatory barriers, resulting in scarce human clinical trial ...